|
Mechanism5-HT2A receptor antagonists [+3] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date27 Sep 1996 |
100 Clinical Results associated with Glenmark Pharmaceuticals s.r.o.
0 Patents (Medical) associated with Glenmark Pharmaceuticals s.r.o.
100 Deals associated with Glenmark Pharmaceuticals s.r.o.
100 Translational Medicine associated with Glenmark Pharmaceuticals s.r.o.